Ran‐binding protein 3 (RanBP3) may be a promising prognostic biomarker and therapeutic target in CRC, and a preclinical rationale is provided for NU2058 as a potential strategy for cancer treatment. Here, RANBP3 is linked to colorectal carcinoma.